This is a working overview of freeze-thaw cycling, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-09 and is reviewed periodically as new material appears.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized powder form |
| Solubility class | Freely soluble in water | Also dissolves in polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or lower | Desiccated and protected from light |
| Typical analytical method | Reversed-phase HPLC with UV detection | Purity reported by area normalization |
| Common synonyms | PT-141; bremelanotide | Research code and assigned generic name |
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Transfusion medicine (or transfusiology) is the branch of medicine that encompasses all aspects of the transfusion of blood and blood components including aspects related to hemovigilance. It includes issues of blood donation, immunohematology and other laboratory testing for transfusion-transmitted diseases, management and monitoring of clinical transfusion practices, patient blood management, therapeutic apheresis, stem cell collections, cellular therapy, and coagulation. Laboratory management and understanding of state and federal regulations related to blood products are also a large part of the field.
These results highlight the clinical translation of α-amanitin’s cell-cycle-independent mechanism, which effectively targets both proliferating tumor cells and quiescent cancer stem cells. The ATAC platform is also advancing into solid tumors. TROP2-targeted conjugates based on the hRS7 antibody achieved complete tumor eradication in patient-derived xenograft models of pancreatic cancer and triple-negative breast cancer, outperforming the approved ADC sacituzumab govitecan. In January 2026, Takeda initiated a Phase I/II clinical trial of an ATAC candidate for solid tumors.
Lumen stenosis that is greater than 75% was considered the hallmark of clinically significant disease in the past because recurring episodes of angina and abnormalities in stress tests are only detectable at that particular severity of stenosis. However, clinical trials have shown that only about 14% of clinically debilitating events occur at sites with more than 75% stenosis. Most cardiovascular events involve the sudden rupture of plaque, but do not display any evident luminal narrowing. Thus, greater attention has been focused on "vulnerable plaque" since the late 1990s. Besides the traditional diagnostic methods such as angiography and stress testing, other detection techniques have been developed in the past decades for earlier detection of atherosclerotic disease. Some of the detection approaches include anatomical detection and physiological measurement. Examples of anatomical detection methods include coronary calcium scoring by CT, carotid IMT (intimal media thickness) measurement by ultrasound, and intravascular imaging techniques, such as intravascular ultrasound (IVUS), and intravascular optical coherence tomography (OCT), allowing direct visualization of atherosclerotic plaques. Other methods include blood measurements, e.g., lipoprotein subclass analysis, HbA1c, hs-CRP, and homocysteine. Both anatomic and physiologic methods allow early detection before symptoms appear, disease staging, and tracking of disease progression.
== History of the taxonomy == Prior to 1993, the family Conidae contained only Conus species. In 1993 significant taxonomic changes were proposed by Taylor, et al.,: the family Conidae was redefined as several subfamilies. The subfamilies included many subfamilies that had previously been classified in the family Turridae, and the Conus species were moved to the subfamily Coninae. In further taxonomic changes that took place in 2009 and 2011, based upon molecular phylogeny (see below), the subfamilies that were previously in the family Turridae were elevated to the status of families in their own right. This left the family Conidae once again containing only those species that were traditionally placed in that family: the cone snail species.
Poppenian Hymal (ポッペン星人ハイマル, Poppen Seijin Haimaru): A crescent moon–themed alien from Planet Poppen who previously worked with Swan Shiratori and was jealous of her after she was chosen for the Police Scientific Criminal Investigation Laboratory, over him. After remotely operating and allowing the Kaijuki Devil Capture 6 (デビルキャプチャー6, Debiru Kyapuchā Shikkusu) to be destroyed while gathering data on the Dekarangers' mecha, he assists Agent Abrella in constructing the composite dinosaur-themed Kaijuki, Frankenzaurus (フランケンザウルス, Furankenzaurusu), using parts from Fan Crusher, Devil Capture 2, Shinobi Shadow, Terrible Terror, God Pounder, and Million Missile, and powered with a Hymal Reactor. Remotely operating Frankenzaurus, Hymal temporarily overpowers the Dekarangers until he is confronted by Deka Swan, is betrayed by Abrella after he sets Frankensaurus' Hymal Reactor to explode, and is forced to shut the reactor down before it does so. After the Dekarangers destroy Frankenzaurus with the Deka Wing Cannon, Hymal attempts to commit suicide, but Swan talks him out of it before Tetsu arrests him. Hymal is voiced by Naoki Tatsuta (龍田 直樹, Tatsuta Naoki). Mikean Teresa (マイク星人テレサ, Maiku Seijin Teresa): A singer, guitarist, and Hoji's girlfriend from Planet Mike, who suffers from a terminal disease after working on a dangerous mining planet years prior. Her younger brother Clord worked on a cure, but it involved stealing nutrients from other young women. Upon learning of Clord's crimes, an emotionally torn Hoji deletes him before breaking up with Teresa.
Sources: en.wikipedia.org
His explorations on Pichincha included documenting frequent earthquakes, which led to local rumors attributing the tremors to his presence. Humboldt’s work during this period advanced scientific understanding of high-altitude geology and volcanology.
== History == Paliperidone palmitate was first approved by the United States Food and Drug Administration (FDA) on July 31, 2009, under the brand name Invega Sustenna, for the acute and maintenance treatment of schizophrenia in adults. Health Canada followed on June 30, 2010, issuing a Notice of Compliance for the same indication. Australia's Therapeutic Goods Administration registered the product on July 28, 2010. The European Medicines Agency (EMA) authorized the once‑monthly injection under the brand name Xeplion on March 4, 2011. In China, the drug was approved in January 2012 and launched later that year under the brand name Shansida (善思达); marketed by Xian-Janssen Pharmaceutical Limited (which is the Janssen (Johnson & Johnson) subsidiary in China), it was the first once-monthly long-acting injectable atypical antipsychotic available in the country. The approval was based on a multi-center clinical trial funded by Xian-Janssen Pharmaceutical Ltd. which demonstrated that Shansida monotherapy was non-inferior to a combination of oral risperidone and long-acting injectable risperidone microspheres (brand name Risperdal Consta) for acute schizophrenia. In Japan, the once‑monthly injection was approved in September 2013 under the brand name Xeplion (ゼプリオン, Zepurion) and was launched on November 19, 2013. Globally, the paliperidone palmitate long-acting injectable market was valued at approximately US$4.1 billion in 2024 and is projected to reach US$6.3 billion by 2031.
== Conferences == In May 2010, the Foundation sponsored a conference on "Creatine in Health, Medicine and Sport", held at Downing College, Cambridge. This was followed by the first Macular Carotenoids Conference also held at Downing College in July 2011 which led to a book, Carotenoids and Retinal Disease. Further conferences on Macular Carotenoids at Downing College were held in 2013 and 2015. The BON (Brain and Ocular Nutrition) Conference is to be held 11–13 July 2018 again at Downing College, Cambridge.
Passing alpha particles through a very thin glass window and trapping them in a discharge tube allowed researchers to study the emission spectrum of the captured particles, and ultimately proved that alpha particles are helium nuclei. Other experiments showed beta radiation, resulting from decay and cathode rays, were high-speed electrons. Likewise, gamma radiation and X-rays were found to be high-energy electromagnetic radiation. The relationship between the types of decays also began to be examined: For example, gamma decay was almost always found to be associated with other types of decay, and occurred at about the same time, or afterwards. Gamma decay as a separate phenomenon, with its own half-life (now termed isomeric transition), was found in natural radioactivity to be a result of the gamma decay of excited metastable nuclear isomers, which were in turn created from other types of decay. Although alpha, beta, and gamma radiations were most commonly found, other types of emission were eventually discovered. Shortly after the discovery of the positron in cosmic ray products, it was realized that the same process that operates in classical beta decay can also produce positrons (positron emission), along with neutrinos (classical beta decay produces antineutrinos).
Cell surface receptors play an essential role in the biological systems of single- and multi-cellular organisms and malfunction or damage to these proteins is associated with cancer, heart disease, and asthma. These trans-membrane receptors are able to transmit information from outside the cell to the inside because they change conformation when a specific ligand binds to it. There are three major types: Ion channel linked receptors, G protein–coupled receptors, and enzyme-linked receptors.
Sources: en.wikipedia.org
Thyroid storm is a severe form of thyrotoxicosis characterized by rapid and often irregular heartbeat, high temperature, vomiting, diarrhea, and mental agitation. Symptoms may not be typical in the young, old, or pregnant. It usually occurs due to untreated hyperthyroidism and can be provoked by infections. It is a medical emergency and requires hospital care to control the symptoms rapidly. The mortality rate in thyroid storm is 3.6-17%, usually due to multi-organ system failure.
=== Tendonopathy === Tendinopathy refers to a spectrum of tendon disorders, including tendinitis and tendinosis, characterized by pain, swelling, and impaired function of the tendon. Tendon rupture involves the partial or complete tear of the tendon, which can occur acutely or as a result of chronic degeneration. Both conditions are common in athletes and the aging population, but effective treatments and therapies remain limited due to an incomplete understanding of the underlying biology.
=== Synthesis === To synthesize dexamethasone, 16β-methylprednisolone acetate is dehydrated to the 9,11-dehydro derivative. This is then reacted with a source of hypobromite, such as basic N-bromosuccinimide, to form the 9α-bromo-11β-hydrin derivative, which is then ring-closed to an epoxide. A ring-opening reaction with hydrogen fluoride in tetrahydrofuran gives dexamethasone.
== Example values == A PDCAAS value of 1 is the highest, and 0 the lowest. The table shows the ratings of selected foods. Parenthesized values reflect the value without truncation. A few more values can be found in Boye et al. 2012. Note the use of several different scoring profiles in this work: "updated" versions of PDCAAS may use profiles different from the 1993 original.
Sources: en.wikipedia.org
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.
Retention time supports consistency but does not establish structure by itself. A different compound can elute at a similar time under one set of conditions. Mass spectrometry or comparison with a verified standard is normally required alongside the chromatographic result.
The lactam bridge constrains the peptide backbone and limits attack by some exopeptidases. It does not protect against hydrolysis of amide bonds inside the ring or against oxidative modification of susceptible residues. Stability therefore still depends heavily on storage conditions.
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.